Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRXFree Report) by 2.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,329,508 shares of the company’s stock after acquiring an additional 26,875 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.43% of Amneal Pharmaceuticals worth $8,070,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMRX. Rubric Capital Management LP lifted its position in Amneal Pharmaceuticals by 54.7% during the 3rd quarter. Rubric Capital Management LP now owns 4,024,500 shares of the company’s stock worth $16,983,000 after acquiring an additional 1,423,121 shares during the period. Phocas Financial Corp. acquired a new stake in Amneal Pharmaceuticals during the 4th quarter worth about $4,339,000. Vanguard Group Inc. lifted its position in Amneal Pharmaceuticals by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company’s stock worth $57,174,000 after acquiring an additional 412,599 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Amneal Pharmaceuticals by 122.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 515,233 shares of the company’s stock valued at $2,174,000 after buying an additional 283,524 shares during the last quarter. Finally, EAM Investors LLC purchased a new position in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $972,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Analyst Ratings Changes

AMRX has been the topic of a number of recent research reports. Piper Sandler upped their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 4th. The Goldman Sachs Group upped their target price on Amneal Pharmaceuticals from $6.25 to $8.00 and gave the stock a “buy” rating in a research note on Monday, May 6th. Finally, Truist Financial restated a “buy” rating and issued a $9.00 target price (up previously from $7.00) on shares of Amneal Pharmaceuticals in a research note on Monday, May 6th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $8.25.

Check Out Our Latest Analysis on Amneal Pharmaceuticals

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $6.68 on Friday. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -11.93 and a beta of 1.33. Amneal Pharmaceuticals, Inc. has a twelve month low of $2.22 and a twelve month high of $6.98. The company has a current ratio of 1.65, a quick ratio of 0.97 and a debt-to-equity ratio of 121.31. The stock has a 50-day moving average of $6.18 and a 200 day moving average of $5.66.

Amneal Pharmaceuticals (NASDAQ:AMRXGet Free Report) last released its quarterly earnings results on Friday, May 3rd. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. The company had revenue of $659.19 million during the quarter, compared to analysts’ expectations of $623.08 million. Amneal Pharmaceuticals had a positive return on equity of 234.06% and a negative net margin of 6.76%. Sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.51 EPS for the current fiscal year.

About Amneal Pharmaceuticals

(Free Report)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Read More

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRXFree Report).

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NASDAQ:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.